Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Lesaffre International | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Soccer players display elevated inflammatory and oxidative stress markers combined with reduced soccer specific performance over a 72-hour period. However, in modern soccer, players participate very often in 2 or 3 matches within a week, with a recovery period of 72 hours between successive matches, that is insufficient to restore skeletal muscle homeostasis and performance. Of note, reduced glutathione (GSH) levels, a tripeptide consisting of the amino acids cysteine, glycine and glutamic acid, are substantially reduced during the 72-hour recovery period after a match because of the trauma-related acute inflammatory and oxidative stress response. GSH availability is a crucial regulator of cellular redox status, affecting numerous intracellular and physiological processes such as redox signalling, immunoregulation and muscle metabolism. Indeed, enhanced GSH availability following muscle damaging exercise has been shown to be beneficial for skeletal muscle and performance recovery by mitigating the inflammatory and oxidative stress response. Thus, the enhancement of GSH availability through dietary interventions would be a promising strategy to accelerate skeletal muscle and performance recovery following a soccer game. S-Acetyl Glutathione (SAG) is a glutathione precursor with enhanced absorption kinetics due to chemical S-acetylation of the thiol group on the cysteinyl amino acid of GSH and oral administration of SAG has been shown to be more effective in restoring intracellular glutathione levels compared to oral glutathione. The aim of this study is to (i) perform a pharmacokinetic assessment of 200 mg/day vs 500 mg/day of SAG during a 7-day supplementation period (pre-loading) and (ii) to establish the pharmacodynamic effect of the two dosages at 24, 48 and 72h following a 90-minute official soccer match.
Following baseline testing [including assessment of anthropometrics, body composition (via DXA instrumentation) and physical performance (cardiorespiratory fitness, drop jump and countermovement jump performance, repeated sprint anility, isokinetic peak torque)], 20 well-trained, soccer players will participate in three trials, receiving daily (i) 200 mg SAG, (ii) 500 mg SAG or (iii) Placebo, according to a randomized, double-blind, crossover, repeated-measures design. The duration of each trial will be 11 days, including a 7-day pre-loading period (days 1 -7), a match day (day 8) and 3 consecutive recovery days after the match (days 9-11). Between trials a 3-week washout period will be implemented.
Pre-loading period: During the 7-day pre-loading period players will participate daily in training sessions according to a soccer-specific weekly training schedule, while receiving the respective supplement. Blood samples will be collected on day 1 and day 7 while daily nutrient intake (via 7-day diet recalls), physical activity level (via accelerometry) and training load (via global positioning system instrumentation during training sessions) will be monitored daily.
Match day: On match day, players will participate in an official 90-min soccer match. Field activity (total distance, average and maximum speed, high intensity running, high speed running, accelerations, decelerations) and heart rate (mean and maximum heart rate) will be continuously monitored using global positioning system (GPS) and heart rate monitors, respectively.
Recovery days: During the 3-day recovery period after the match, players will participate daily in (i) morning testing sessions and (ii) training sessions in the evening. Testing sessions will include blood sampling and performance measurements including drop jump and countermovement jump performance, repeated sprint anility, isokinetic peak torque and muscle soreness (DOMS). Dietary intake (via a 3-day diet recalls), physical activity level (via accelerometry) and training load (via GPS instrumentation during training sessions) will be monitored daily.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| SAG-200 Trial | Experimental | Oral administration of S-Acetyl Glutathione (SAG) |
|
| SAG-500 Trial | Experimental | Oral administration of S-Acetyl Glutathione (SAG) |
|
| Placebo Trial | Placebo Comparator | Oral administration of placebo |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| 200 mg S-Acetyl Glutathione | Dietary Supplement | Participants will be supplemented daily with 200 mg of S-acetyl glutathione, orally, over the 11-day experimental period. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in creatine kinase levels | Creatine kinase concentration will be measured in serum using a Clinical Chemistry Analyzer | Day 1, day 7, day 9, day 10 and day 11 |
| Change in myoglobin levels | Myoglobin concentration will be measured in serum using a Clinical Chemistry Analyzer | Day 1, day 7, day 9, day 10 and day 11 |
| Change in reduced glutathione | Reduced glutathione will be photometrically determined in red blood cell lysates using a spectrophotometer | Day 1, day 7, day 9, day 10 and day 11 |
| Change in oxidized glutathione | Oxidized glutathione will be photometrically determined in red blood cell lysates using a spectrophotometer | Day 1, day 7, day 9, day 10 and day 11 |
| Change in glutathione reductase activity | Glutathione reductase activity will be photometrically determined in red blood cell lysates using a spectrophotometer | Day 1, day 7, day 9, day 10 and day 11 |
| Change in glutathione peroxidase activity | Glutathione peroxidase activity will be photometrically determined in red blood cell lysates using a spectrophotometer | Day 1, day 7, day 9, day 10 and day 11. |
| Change in catalase activity | Catalase activity will be photometrically determined in red blood cell lysates using a spectrophotometer |
| Measure | Description | Time Frame |
|---|---|---|
| Change in total distance covered | Total distance (km) covered during training and match play will be monitored using Global Positioning System (GPS) | Daily throughout the 11-day experimental period |
| Change in internal load |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Dimitrios Draganidis, PhD | Contact | +30 2431047078 | ddraganidis@uth.gr | |
| Athanasios Poulios, PhD | Contact | +30 2431047053 | athanpoul@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Dimitrios Draganidis, PhD | University of Thessaly, Department of Physical Education and Sport Science | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Physical Education and Sport Science, University of Thessaly | Trikala | Karies | 42100 | Greece |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 500 mg S-Acetyl Glutathione | Dietary Supplement | Participants will be supplemented daily with 500 mg of S-acetyl glutathione, orally, over the 11-day experimental period. |
|
| Placebo Supplementation | Dietary Supplement | Participants will be supplemented daily with placebo, orally, over the 11-day experimental period. |
|
| Day 1, day 7, day 9, day 10 and day 11 |
| Change in superoxide dismutase activity | Superoxide dismutase activity will be photometrically determined in red blood cell lysates using a spectrophotometer | Day 1, day 7, day 9, day 10 and day 11 |
| Change in maximal voluntary isometric contraction | Maximal voluntary isometric contraction will be assessed at a 60o knee joint angle, in both dominant and non-dominant limb, using an isokinetic dynamometer | Day 1, day 9, day 10 and day 11 |
| Change in maximal peak torque | Maximal concentric and eccentric peak torque at 60o/s of the knee extensors and flexors in both dominant and non-dominant limb, will be assessed on an isokinetic dynamometer | Day 1, day 9, day 10 and day 11 |
| Change in jumping performance | Countermovement jump and drop jump performance will be tested using an optical measurement system consisting of a transmitting and receiving bar | Day 1, day 9, day 10 and day11 |
| Change in repeated sprint ability | Repeated sprint ability will be assessed by performing 5x25 m sprints interspersed by a 25-seconds recovery period using infrared photocells | Day 1, day 9, day 10 and day 11 |
| Change in delayed onset muscle soreness (DOMS) | DOMS will be assessed using a 10-scale visual analogue scale | Day 1, day 9, day 10 and day 11 |
Heart rate during training sessions and the match will be monitored using heart rate monitors
| Daily throughout the 11-day experimental period |
| Change in dietary intake | Dietary intake will be assessed using diet recalls | Daily throughout the 11-day experimental period |
| Change in time spent in moderate-to-vigorous physical activity | The time (minutes) spent in moderate-to-vigorous physical activity on a daily basis will be monitored using accelerometers | Daily throughout the 11-day experimental period |
| Change in distance covered with high-intensity running | Distance (km) covered with high-intensity running during training and match play will be monitored using Global Positioning System (GPS) | Daily throughout the 11-day experimental period |
| Change in distance covered with sprinting | Distance (km) covered with high-intensity sprinting during training and match play will be monitored using Global Positioning System (GPS) | Daily throughout the 11-day experimental period |
| Change in accelerations | The number of accelerations performed during training and match play will be monitored using Global Positioning System (GPS) | Daily throughout the 11-day experimental period |
| Change in decelerations | The number of decelerations performed during training and match play will be monitored using Global Positioning System (GPS) | Daily throughout the 11-day experimental period |
| Change in total step count | The total number of steps performed daily will be monitored using accelerometers | Daily throughout the 11-day experimental period |
| Change in physical activity-related energy expenditure | Energy expenditure (kcal) related to habitual physical activity will be assessed using accelerometers | Daily throughout the 11-day experimental period |